Managing Biosimilars: A Specialty All Its Own
Topics: Implementation
106 Results
Accelerating the Adoption of Biosimilars
Topics: Implementation
Biosimilar Approvals
Topics: Legal / Regulatory
What biosimilars have been approved in the United States?
Topics: Legal / Regulatory
Biosimilar Comparable in Safety, Efficacy to Tysabri in Phase 3 Trial
Topics: Multiple Sclerosis
Efficacy and safety of proposed natalizumab biosimilar PB006 versus Tysabri® in patients with relapsing remitting multiple sclerosis: Primary data from the Phase III Antelope study (P6-4.003)
Topics: Multiple Sclerosis
Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations
Topics: Multiple Sclerosis
Guidelines for Approval of DMT Biosimilars, Use In Europe Drafted
Topics: Multiple Sclerosis
Biosimilar to Tysabri for Relapsing-Remitting MS Is On Its Way
Topics: Multiple Sclerosis
Eye on Pharma: Natalizumab Injunction; Oral Ustekinumab Development; New Study for Secukinumab Biosimilar
Topics: Multiple Sclerosis
Applications for proposed first-of-a-kind multiple sclerosis biosimilar natalizumab accepted by US FDA and EMA
Topics: Multiple Sclerosis
Sandoz Submits 351(k) Application for Biosimilar Natalizumab to Treat MS
Topics: Multiple Sclerosis
New Biosimilar Product Checklist
Topics: Implementation
Monograph Presentation Checklist
Topics: P&T Committee
P&T Implementation Checklist
Topics: P&T Committee
How to select a best-value biological medicine? A practical model to support hospital pharmacists
Topics: Economics, Implementation
Healthcare system conversion to a biosimilar: Trials and tribulations
Topics: P&T Committee
A Patient’s Guide to Understanding Biosimilars
Topics: Implementation
Formulary Monograph Services
Topics: P&T Committee
Biosimilars in the U.S.: Reimbursement and Impacts to Uptake
Topics: Implementation, Payers
Page 5 of 6